Sutent 50mg Capsule (Sunitinib)

The Sutent 50mg capsule (sunitinib) is a targeted anticancer medicine that contains sunitinib as an active ingredient. It is used in the treatment of kidney cancer, pancreatic neuroendocrine tumors, and gastrointestinal stromal tumor. The medicine belongs to the drug class of tyrosine kinase inhibitor. It works by blocking the specific protein called tyrosine kinase that drives cancer growth and the formation of new blood vessels, leading to tumor. By inhibiting these pathways, it helps slow or decrease the growth and spread of cancer cells. The Sunitinib 50mg capsule is typically prescribed as a standalone targeted therapy but also in specific combination therapy.

The capsule must be taken orally and swallowed whole with water and should not be crushed, chewed, or opened. The prescribed dose and duration of the Sunitinib 50mg capsule depend on the patient's condition and response to treatment. It can also be taken with or without food. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include tiredness, weakness, nausea, vomiting, diarrhea, loss of appetite, abdominal discomfort, mouth sores, changes in taste, skin discoloration, and hand-foot syndrome. A few patients can undergo severe side effects, including severe bleeding, heart problems, high blood pressure, liver damage, kidney problems, and thyroid dysfunction. Most of the Sunitinib 50mg capsule side effects tend to resolve when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

The medicine may harm an unborn baby and should not be used during pregnancy. Inform your doctor before undergoing surgery or dental procedures because the drug may affect wound healing. Patients must list all medicines, supplements, and herbal products that they are taking. The Sunitinib 50mg capsule must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Kidney cancer and Gastrointestinal stromal tumors and Pancreatic Neuroendocrine Tumors

Like other anticancer medicines, Sutent 50mg Capsule (Sunitinib 50mg) also has some common to severe side effects. These undesired symptoms are observed in the body after taking this medicine and usually disappear with time as the body adjusts to the medicine.

Common Side Effects Include the Following:
● Decreased appetite
● Mucositis
● High blood pressure
● Hand-foot syndrome
● Bleeding disorder
● Taste change
● Nausea
● Vomiting
● Weakness
● Fatigue
● Diarrhea
The above-mentioned effects don't need any special medical attention, but if any side effects worsen, report to your doctor immediately.

The recommended dose of Sutent 50mg Capsule (Sunitinib 50mg) may vary according to the type & stage of cancer, or age, weight, and other health factors of the patients. This capsule should be swallowed as a whole with water, and do not crush, chew, or open it. It is usually taken once a day, with or without food, at a fixed time each day. Don't miss a dose or double the dose to compensate for the missed dose.

● Motzer, R. J., Michaelson, M. D., Rosenberg, J., Bukowski, R. M., Curti, B. D., George, D. J., ... & Wilding, G. (2007). Sunitinib efficacy against advanced renal cell carcinoma. The Journal of urology, 178(5), 1883-1887.
● Motzer, R. J., Escudier, B., Gannon, A., & Figlin, R. A. (2017). Sunitinib: ten years of successful clinical use and study in advanced renal cell carcinoma. The oncologist, 22(1), 41-52.
● Raymond, E., Dahan, L., Raoul, J. L., Bang, Y. J., Borbath, I., Lombard-Bohas, C., ... & Ruszniewski, P. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine, 364(6), 501-513.
● Gan, H. K., Seruga, B., & Knox, J. J. (2009). Sunitinib in solid tumors. Expert opinion on investigational drugs, 18(6), 821-834.
● Rini, B. I. (2007). Sunitinib. Expert opinion on pharmacotherapy, 8(14), 2359-2369.